An Open Label, Phase II Investigator-Initiated Study of Venetoclax and Eprenetapopt (APR-246) in Previously Treated Relapsed/Refractory Patients With Mantle Cell Lymphoma (MCL)
Latest Information Update: 14 Mar 2022
At a glance
- Drugs Eprenetapopt (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 23 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Aug 2021 New trial record